HDL and chronic kidney disease.

Area of Science:

• Lipid metabolism
• Nephrology
• Cardiovascular research

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is a hallmark of dyslipidemia in chronic kidney disease (CKD).
• In CKD, HDL particles undergo structural and functional changes, losing atheroprotective properties and potentially becoming detrimental.
• Reduced HDL-C levels are uniquely associated with CKD progression.

Purpose of the Study:

• To review alterations in HDL structure and function in CKD.
• To explore the link between genetic HDL metabolism defects and kidney dysfunction.
• To discuss targeting the HDL system as a strategy to slow CKD progression.

Main Methods:

• Literature review of studies on HDL metabolism in CKD.
• Analysis of genetic mutations affecting HDL components (e.g., APOA1, APOE, APOL, LCAT).
• Examination of LCAT deficiency as a model for CKD-associated lipid abnormalities.

Main Results:

• CKD is associated with dysfunctional HDL particles that lose protective functions.
• Genetic defects in HDL metabolism, particularly LCAT deficiency, mirror lipid abnormalities seen in CKD.
• Reduced HDL-C levels are a significant indicator of CKD progression.

Conclusions:

• HDL dysfunction plays a critical role in CKD pathogenesis and progression.
• Genetic factors influencing HDL metabolism are implicated in kidney disease.
• Modulating the HDL system presents a potential therapeutic avenue for managing CKD.